Comments
Dr Reddy’s Laboratories on Wednesday announced the launch of Atomoxetine capsules used to treat attention-deficit hyperactivity disorder (ADHD) in the US market.
The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and the company’s Straterra, Dr Reddy’s Laboratories said in a statement.
As per the IMS Health sales data, the Strattera brand had the US sales of around $304 million for the most recent 12 months ending in August 2018.
Shares of Dr Reddy’s Laboratories were 2.20 per cent down at ₹ 2,540.70 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.